Kaushiki M.
About Kaushiki M.
Kaushiki M. is the Director of Oncology (Business Insights and Analytics) at Bristol Myers Squibb in New Jersey, United States, with extensive experience in oncology pipeline strategy and development.
Current Role at Bristol Myers Squibb
Kaushiki M. currently serves as the Director of Oncology (Business Insights and Analytics) at Bristol Myers Squibb in New Jersey, United States. In this role, she is responsible for leading the strategic development of early-stage oncology pipeline insights, leveraging her extensive experience in oncology pipeline strategy and development.
Previous Positions at Bristol Myers Squibb
Prior to her current position, Kaushiki M. held the role of Tour of Duty - Relatlimab Commercial for 6 months in 2021 in New Jersey, where she worked on the commercial strategy for Relatlimab. From 2019 to 2021, she served as Associate Director - Oncology (Business Insights and Analytics) in the Greater New York City Area, contributing significantly to business insights and analytics for oncology.
Consulting Experience at QuintilesIMS
Kaushiki M. has substantive consulting experience in the healthcare and pharmaceuticals industry, having worked as a Consultant at QuintilesIMS for 3 years from 2016 to 2019 in Plymouth Meeting, Pennsylvania. During this tenure, she focused on providing strategic consultancy services within the healthcare sector.
Expertise in Oncology Pipeline Strategy
With a robust background in oncology pipeline strategy and development, Kaushiki M. has successfully led the strategic development of early-stage oncology pipeline insights at Bristol Myers Squibb. Her expertise has been critical in shaping the direction and commercial success of oncology products in development.
Role in Relatlimab Commercial Strategy
During her tenure as Tour of Duty - Relatlimab Commercial at Bristol Myers Squibb, Kaushiki M. had a key role in devising the commercial strategy for Relatlimab. Her insights and strategic direction were instrumental in planning the commercial aspects of this oncology product.